These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 9120291)
1. IL-2 gene delivery within an established murine tumor causes its regression without proliferation of preexisting antitumor-specific CTL. Levraud JP; Duffour MT; Cordier L; Perricaudet M; Haddada H; Kourilsky P J Immunol; 1997 Apr; 158(7):3335-43. PubMed ID: 9120291 [TBL] [Abstract][Full Text] [Related]
2. High frequency of specific CD8+ T cells in the tumor and blood is associated with efficient local IL-12 gene therapy of cancer. Fernandez NC; Levraud JP; Haddada H; Perricaudet M; Kourilsky P J Immunol; 1999 Jan; 162(1):609-17. PubMed ID: 9886439 [TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity. Slos P; De Meyer M; Leroy P; Rousseau C; Acres B Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452 [TBL] [Abstract][Full Text] [Related]
4. Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer. Song K; Chang Y; Prud'homme GJ Gene Ther; 2000 Mar; 7(6):481-92. PubMed ID: 10757021 [TBL] [Abstract][Full Text] [Related]
5. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. Fallarino F; Uyttenhove C; Boon T; Gajewski TF J Immunol; 1996 Feb; 156(3):1095-100. PubMed ID: 8557984 [TBL] [Abstract][Full Text] [Related]
6. Complete recovery of mice from a pre-established tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene. Cordier L; Duffour MT; Sabourin JC; Lee MG; Cabannes J; Ragot T; Perricaudet M; Haddada H Gene Ther; 1995 Jan; 2(1):16-21. PubMed ID: 7712329 [TBL] [Abstract][Full Text] [Related]
7. Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor. Fioretti F; Fradelizi D; Stoppacciaro A; Ramponi S; Ruco L; Minty A; Sozzani S; Garlanda C; Vecchi A; Mantovani A J Immunol; 1998 Jul; 161(1):342-6. PubMed ID: 9647242 [TBL] [Abstract][Full Text] [Related]
8. Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo. Ley V; Langlade-Demoyen P; Kourilsky P; Larsson-Sciard EL Eur J Immunol; 1991 Mar; 21(3):851-4. PubMed ID: 2009918 [TBL] [Abstract][Full Text] [Related]
9. Tumor cell surface expression of granulocyte-macrophage colony-stimulating factor elicits antitumor immunity and protects from tumor challenge in the P815 mouse mastocytoma tumor model. Soo Hoo W; Lundeen KA; Kohrumel JR; Pham NL; Brostoff SW; Bartholomew RM; Carlo DJ J Immunol; 1999 Jun; 162(12):7343-9. PubMed ID: 10358185 [TBL] [Abstract][Full Text] [Related]
10. In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity. Sun Y; Peng D; Lecanda J; Schmitz V; Barajas M; Qian C; Prieto J Gene Ther; 2000 Sep; 7(17):1467-76. PubMed ID: 11001366 [TBL] [Abstract][Full Text] [Related]
11. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells. Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701 [TBL] [Abstract][Full Text] [Related]
12. Differential requirement for CD4 help in the development of an antigen-specific CD8+ T cell response depending on the route of immunization. Bour H; Horvath C; Lurquin C; Cerottini JC; MacDonald HR J Immunol; 1998 Jun; 160(11):5522-9. PubMed ID: 9605156 [TBL] [Abstract][Full Text] [Related]
13. Tumor irradiation followed by intratumoral cytokine gene therapy for murine renal adenocarcinoma. Hillman GG; Slos P; Wang Y; Wright JL; Layer A; De Meyer M; Yudelev M; Che M; Forman JD Cancer Gene Ther; 2004 Jan; 11(1):61-72. PubMed ID: 14681727 [TBL] [Abstract][Full Text] [Related]
14. Circulating levels of IL-10 are critically related to growth and rejection patterns of murine mastocytoma cells. Grohmann U; Silla S; Belladonna ML; Bianchi R; Orabona C; Puccetti P; Fioretti MC Cell Immunol; 1997 Nov; 181(2):109-19. PubMed ID: 9398398 [TBL] [Abstract][Full Text] [Related]
15. Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages. Maas RA; Roest PA; Becker MJ; Weimar IS; Dullens HF; Den Otter W Immunobiology; 1992 Nov; 186(3-4):214-29. PubMed ID: 1490728 [TBL] [Abstract][Full Text] [Related]
16. Induction of antitumor immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinoma. Tanaka M; Saijo Y; Sato G; Suzuki T; Tazawa R; Satoh K; Nukiwa T Cancer Gene Ther; 2000 Nov; 7(11):1481-90. PubMed ID: 11129290 [TBL] [Abstract][Full Text] [Related]
17. Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL. Silla S; Fallarino F; Boon T; Uyttenhove C Eur Cytokine Netw; 1999 Jun; 10(2):181-90. PubMed ID: 10400824 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice. Provinciali M; Argentati K; Tibaldi A Gene Ther; 2000 Apr; 7(7):624-32. PubMed ID: 10819579 [TBL] [Abstract][Full Text] [Related]
19. Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. Fallarino F; Gajewski TF J Immunol; 1999 Oct; 163(8):4109-13. PubMed ID: 10510345 [TBL] [Abstract][Full Text] [Related]
20. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Addison CL; Bramson JL; Hitt MM; Muller WJ; Gauldie J; Graham FL Gene Ther; 1998 Oct; 5(10):1400-9. PubMed ID: 9930346 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]